Original article by Tracy Bowden
abc.net au – Page: Online : 10-Sep-19
Developed by Swiss company Novartis, Kymriah is an innovative immunotherapy treatment that has been described by University of NSW cancer biologist Darren Saunders as a type of living drug. Saunders notes it has shown to be very beneficial for a large number of people with certain types of leukaemia and lymphoma, but not all patients. Dave Roberts, who has a type of lymphoma, says his doctor has told him that Kymriah is basically his only hope of survival. The federal government is not yet funding Kymriah for people with the type of cancer that Roberts has, so treatment would cost him $500,000.
NOVARTIS AG, UNIVERSITY OF NEW SOUTH WALES